TW200719893A - Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery - Google Patents

Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Info

Publication number
TW200719893A
TW200719893A TW095115314A TW95115314A TW200719893A TW 200719893 A TW200719893 A TW 200719893A TW 095115314 A TW095115314 A TW 095115314A TW 95115314 A TW95115314 A TW 95115314A TW 200719893 A TW200719893 A TW 200719893A
Authority
TW
Taiwan
Prior art keywords
dosage forms
sub
pharmaceutical compositions
methods
tenon
Prior art date
Application number
TW095115314A
Other languages
English (en)
Inventor
Channing Rodney Beals
Wesley Warren Day
Deborah Khalil
Karen J Klamerus
Susan Raber
Baldo Scassellati-Sforzolini
Samuel Hyman Zwillich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200719893A publication Critical patent/TW200719893A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
TW095115314A 2005-04-29 2006-04-28 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery TW200719893A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67606005P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
TW200719893A true TW200719893A (en) 2007-06-01

Family

ID=37055940

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095115314A TW200719893A (en) 2005-04-29 2006-04-28 Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Country Status (4)

Country Link
JP (1) JP2006306877A (zh)
AR (1) AR054442A1 (zh)
TW (1) TW200719893A (zh)
WO (1) WO2006117666A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006320535B2 (en) * 2005-11-29 2010-09-23 Glaxosmithkline Llc Treatment method
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
KR20150093819A (ko) * 2012-12-14 2015-08-18 글락소스미스클라인 엘엘씨 약제 조성물
MX2017003928A (es) 2014-09-26 2017-06-28 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada.
JP2018065920A (ja) * 2016-10-19 2018-04-26 中越パルプ工業株式会社 セルロースナノファイバー及びセルロースナノファイバーの製造方法
CN116251186A (zh) * 2021-12-09 2023-06-13 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
MXPA05006676A (es) * 2002-12-19 2005-08-16 Pfizer Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery

Also Published As

Publication number Publication date
AR054442A1 (es) 2007-06-27
WO2006117666A2 (en) 2006-11-09
JP2006306877A (ja) 2006-11-09
WO2006117666A3 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
BRPI0811142A8 (pt) prevenção e tratamento de condições oculares associadas a complementos
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
MX354184B (es) Compuestos alcoxi para el tratamiento de enfermedades.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
EP1765362A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOVASCULAR DISEASES
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
WO2007046083A3 (en) Compositions for treatment of eye diseases
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
TW200719893A (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
TW200626158A (en) Naphthaline derivatives
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
TW200637817A (en) 5-aminoindole derivatives
US20180021403A1 (en) Combination Therapy
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
TW200732304A (en) Piperidine derivatives
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales